This Article Full Text Full Text (PDF) All Versions of this Article: 90/12/6721    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mantovani, G. Articles by Lania, A. G. Search for Related Content PubMed PubMed Citation Articles by Mantovani, G. Articles by Lania, A. G. Related Collections Endocrine Oncology Neuroendocrinology and Pituitary

Effect of Cyclic Adenosine 3',5'-Monophosphate/Protein Kinase A Pathway on Markers of Cell Proliferation in Nonfunctioning Pituitary Adenomas

Institute of Endocrine Sciences (G.M., S.B., B.G., S.C., E.F., E.P., P.B.-P., A.S., A.G.L.), Pathology Unit, Department of Medicine, Surgery and Dentistry (S.F.), and Department of Neurosurgery (M.L., P.R.), Ospedale Maggiore, IRCCS, University of Milan, Milan, Italy

Address all correspondence and requests for reprints to: Dr. Anna Spada, Institute of Endocrine Sciences, Pad. Granelli, Via F. Sforza, 35, 20122 Milan, Italy. E-mail: anna.spada{at}unimi.it.

Context: Alterations in cAMP signaling have been identified as a cause of endocrine neoplasia. In particular, activating mutations of the G_s gene and protein kinase A (PKA) overactivity due to low expression of PKA regulatory subunit 1A (R1A) have been implicated in somatotroph proliferation.

Objective: The objective of this study was to evaluate the effects of cAMP-PKA cascade activation in nonfunctioning pituitary adenomas (NFPA).

Design and Methods: By immunohistochemistry, R1A, R2A, and R2B expression was evaluated in cells obtained from eight surgically removed NFPA positive for gonadotropins. Cyclin D1 expression and ERK1/2 activity were analyzed under basal conditions and after cAMP-PKA cascade activation.

Results: Immunohistochemistry studies demonstrated a low R1/R2 ratio in all NFPA. Additional unbalance of R1/R2 ratio by 8-chloroadenosine cAMP (8-Cl-cAMP) and direct adenylyl cyclase stimulation by forskolin did not increase cyclin D1 expression or ERK1/2 activity in five NFPA (group 1), but even caused 74 ± 15% and 85 ± 13% inhibitions of cyclin D1 and ERK1/2 activity, respectively, in the remaining NFPA (group 2). Moreover, in group 2, PKA blockade by the specific inhibitor PKI increased cyclin D1 expression (96 ± 25% over basal) and ERK1/2 activity (116 ± 28% over basal).

Conclusions: These data show that in contrast with what was previously observed in transformed somatotrophs, activation of the cAMP-PKA pathway did not generate proliferative signals in tumoral cells of the gonadotroph lineage, and in a subset of tumors even exerted a tonic inhibitory effect, thus confirming a different role for the cAMP-mediated pathway in promoting proliferation in the pituitary.

This article has been cited by other articles:

				T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596. [Abstract] [Full Text] [PDF]

				Z. Yin, L. Williams-Simons, A. F. Parlow, S. Asa, and L. S. Kirschner Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis Mol. Endocrinol., February 1, 2008; 22(2): 380 - 387. [Abstract] [Full Text] [PDF]

				M. H. Al-Dhaheri and B. G. Rowan Protein Kinase A Exhibits Selective Modulation of Estradiol-Dependent Transcription in Breast Cancer Cells that Is Associated with Decreased Ligand Binding, Altered Estrogen Receptor {alpha} Promoter Interaction, and Changes in Receptor Phosphorylation Mol. Endocrinol., February 1, 2007; 21(2): 439 - 456. [Abstract] [Full Text] [PDF]